Biocomposites is making its SYNICEM bone cement products available in the UK with immediate effect.
The products have been manufactured for over 25 years by Biocomposites’ subsidiary, Synimed.
Following the launch of SYNICEM antibiotic-loaded preformed spacers in the UK, Biocomposites was already planning to follow this up with the launch of their SYNICEM bone cements. This UK launch has been brought forward to help ease the supply crisis that is currently unfolding.
SYNICEM bone cement products are available as high and low viscosity variants, with and without the antibiotic gentamicin.
Michael Harris, Chief Executive Officer of Biocomposites, said: “The NHS is currently facing an acute bone cement supply crisis, which could lead to thousands of orthopaedic operations such as hip and knee replacements being delayed.
“We at Biocomposites – which is one of the few companies in the world capable of manufacturing bone cement at scale – want to do everything we can to help, so patients do not have to wait any longer than absolutely necessary for their vital operations.
“We have therefore decided to bring forward the launch of our SYNICEM bone cement products in the UK with immediate effect, to make them available as soon as possible.
“We are also doubling capacity at our manufacturing facility, principally to help meet UK demand.
“We believe these measures will go a long way to helping meet NHS demand for bone cement and minimising delays to operations.”
Biocomposites is making its SYNICEM bone cement products available in the UK with immediate effect.
The products have been manufactured for over 25 years by Biocomposites’ subsidiary, Synimed.
Following the launch of SYNICEM antibiotic-loaded preformed spacers in the UK, Biocomposites was already planning to follow this up with the...
Biocomposites is making its SYNICEM bone cement products available in the UK with immediate effect.
The products have been manufactured for over 25 years by Biocomposites’ subsidiary, Synimed.
Following the launch of SYNICEM antibiotic-loaded preformed spacers in the UK, Biocomposites was already planning to follow this up with the launch of their SYNICEM bone cements. This UK launch has been brought forward to help ease the supply crisis that is currently unfolding.
SYNICEM bone cement products are available as high and low viscosity variants, with and without the antibiotic gentamicin.
Michael Harris, Chief Executive Officer of Biocomposites, said: “The NHS is currently facing an acute bone cement supply crisis, which could lead to thousands of orthopaedic operations such as hip and knee replacements being delayed.
“We at Biocomposites – which is one of the few companies in the world capable of manufacturing bone cement at scale – want to do everything we can to help, so patients do not have to wait any longer than absolutely necessary for their vital operations.
“We have therefore decided to bring forward the launch of our SYNICEM bone cement products in the UK with immediate effect, to make them available as soon as possible.
“We are also doubling capacity at our manufacturing facility, principally to help meet UK demand.
“We believe these measures will go a long way to helping meet NHS demand for bone cement and minimising delays to operations.”
Copy to clipboard 
